Nicholas Iannotti is an Oncology physician. OpenAlex indexes 129 publications with 7,267 citations (h-index 26).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1871 SE Tiffany Ave
Suite 100
Port St Lucie, FL 349527585
Telephone
772-335-5666Registry record last updated 15 Jun 2010.
Industry payments
20 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year202510 payments
- Janssen Biotech, Inc.Program year20253 payments
- Gilead Sciences, Inc.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
43.1%PD-1 inhibitor40.2%Pembrolizumab100%Part B, office-administered≥23 patientsAromatase Inhibitor0.9%Anastrozole61%Letrozole33%Exemestane7%Part D<11 patients+ 11 more classes in this area
Musculoskeletal
28.6%RANK Ligand Inhibitor28.6%Denosumab100%Part B, office-administered≥32 patientsDermatology
8.3%Corticosteroid8.2%Methylprednisolone sodium succinate100%Part B, office-administered≥74 patientsHerpesvirus Nucleoside Analog DNA Polymerase Inhibitor0.1%Acyclovir100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Oral EPI-7386 in patients with metastatic castration-resistant prostate cancer.
Journal of Clinical Oncology
2023 - Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study
Cancer Research Communications
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”